Loading...
menu
Search
Features
Markets
News
Resources
Pricing
Home
ETF
MRKR
MRKR
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
Latest MRKR ETF News Today | Earnings, Events & Price Alerts
MRKR News
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Dec 19 2025
NASDAQ.COM
Merakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium
Dec 11 2025
Globenewswire
Marker Therapeutics Announces Financial Results for Q3 2025 and Shares Business Developments
Nov 14 2025
Newsfilter
Marker Therapeutics to Present MT-601 Data for Relapsed Non-Hodgkin and Hodgkin Lymphoma at 67th ASH Annual Meeting
Nov 03 2025
Newsfilter
Marker Therapeutics Shares Decline Following Lymphoma Treatment Report
Aug 26 2025
Benzinga
Marker Therapeutics Shares Positive Progress in Phase 1 APOLLO Study with Promising Response Rates in Relapsed Lymphoma
Aug 26 2025
Newsfilter
Dow Jumps Over 100 Points; PepsiCo Posts Upbeat Earnings
Jul 17 2025
Benzinga
Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma
Jun 17 2025
Newsfilter
Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
May 20 2025
Newsfilter
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
May 19 2025
Newsfilter
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
Mar 31 2025
Newsfilter
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Mar 05 2025
Benzinga
Marker Therapeutics initiated with a Buy at Brookline
Feb 10 2025
Business Insider
Insider Purchase: 10% owner at $MRKR (MRKR) Buys 554,250 Shares
Dec 23 2024
NASDAQ.COM
Marker Therapeutics Updates APOLLO Study In Relapsed Lymphoma, Announces $16.1 Mln Private Placement
Dec 19 2024
Business Insider
Marker Therapeutics Announces $16.1 Million Private Placement
Dec 19 2024
Newsfilter
Show More News
